Possible novel cognitive anti-ageing targets identified
Researchers have shown that two epigenetic regulators could be targeted to improve cognitive and behavioural decline in age-related diseases like Alzheimer’s.
List view / Grid view
Researchers have shown that two epigenetic regulators could be targeted to improve cognitive and behavioural decline in age-related diseases like Alzheimer’s.
Researchers have shown that by effectively resetting the microglia, recovery of mice after a traumatic brain injury (TBI) was improved.
A study has shown that the RCAN1 gene plays a role in regulating synaptic plasticity, which contributes to a sympom of Down syndrome.
Neuropathologic similarities between dolphins and humans suggest that the former could act as an effective model for the study of diseases such as Alzheimer’s. Professor Giovanni Di Guardo explains why dolphins could provide researchers with a new window into neurodegenerative conditons.
Researchers have shown that, when treated with L-serine, a non-human primate model of ALS had fewer pathologies associated with the disease.
Research has found that after stroke in mice, B cells migrate to far regions of the brain that control motor functions, indicating their role in recovery.
A molecule has been shown to increase dopamine levels in the brains of mice, offering hope for stopping the progression of Parkinson’s.
Researchers have discovered that neuronal necrosis occurs in Alzheimer's earlier than previously though and revealed the YAP protein as a potential target.
Researchers have engineered a chip which allows 3D modelling of the blood-brain-barrier and has provided insight into how astrocytes facilitate transport of molecules.
A research team has shown that a key difference between neurogenic and non-neurogenic tissues is cross-linking proteins causing stiffness, a discovery that could be used to create new brain injury therapies.
Researchers have revealed that the disruption of oligodendrocytes, which produce myelin, may be a cause of autism spectrum disorder, so presents a therapeutic target.
To address the receptor dysfunction associated with several neurological diseases, scientists have provided novel insights into a protein-protein interaction that could lead to more effective treatments.
Researchers have screened thousands of drugs to discover that C1 effectively blocks the production of amyloid fibrils, so could be an effective therapeutic.
Researchers have conducted a genetic screen in mice to discover a family of genes that contributes to the development of Huntington's.
Research identified a small molecule that targets the mRNA of α-synuclein and prevents the formation of the protein, an approach which could provide novel neurodegeneration therapies.